rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BDRX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Biodexa reports progress on FAP and GIST drug trials
      Nov 9Investing.comBDRX
      Biodexa provides R&D Update

      November 9, 2026Biodexa provides R&D Update Phase 3 Serenta trial in FAP is now two-thirds recruitedPreparations advanced for Phase 1 trial of...

      Nov 9Business InsiderBDRX
      12 Health Care Stocks Moving In Wednesday's After-Market Session - Biodexa Pharmaceuticals (NASDAQ:BDRX),

      Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 13.3% to $0.55 during Wednesday's after-market session. Impact BioMedical (AMEX:IBO) stock rose 10.77% to $3.77. The company's market cap stands at

      Oct 14BenzingaBDRX
      Biodexa Reaches 100-Patient Enrollment Milestone in Phase 3 Serenta Trial as Key Analysis Timeline Accelerates
      Oct 13Yahoo FinanceBDRX
      Biodexa enrolls 100 patients in phase 3 FAP trial Serenta
      Oct 13Investing.comBDRX
      Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP

      October 13, 2026 Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP Update on expected timing of pre-specified futility analysis and database lock Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has enrolled 100 patients in its registration

      Oct 13Yahoo FinanceBDRX
      The Longview: Fireside Chat with Biodexa CEO Stephen Stamp

      Today's interview with Stephen Stamp, CEO of (NASDAQ:BDRX) is about the Company's lead program, eRapa in Familial Adenomatous Polyposis (FAP), a genetic disease of the lower GI tract for which the only current remedy is surgical removal of the colon and/or rectum.Key takeaways: eRapa is an oral drug candidate designed to reduce or eliminate the need for surgical treatments; a Phase 3 registrational trial, running at 29 U.

      Sep 23Yahoo FinanceBDRX
      12 Health Care Stocks Moving In Tuesday's Pre-Market Session
      Sep 15BenzingaBDRXVERA
      Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds

      Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds September 15, 2026 Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 2,2

      Sep 15Yahoo FinanceBDRX
      Corning, Cellectis, Biodexa Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
      Sep 14BenzingaBDRXCLLSGLW
      12 Health Care Stocks Moving In Friday's Intraday Session
      Sep 11BenzingaBDRX

      This is the newest page. Registered accounts read further back.